Uticaj biološke terapije na poboljšanje kvaliteta života pacijenata sa psorijazom
Abstract
Psoriasis is a chronic, inflammatory, relapsing, non-infectious dermatosis and is associated with impaired health related quality of life (HRQoL). Тhere is still insufficient evidence from routine clinical practice regarding the biological therapy impact on the quality of life for patients with psoriasis. The aim of this study was to examine the effectiveness of biological therapy on HRQoL in patients with psoriasis.Methods: We performed an prospective observational pilot study being conducted at the Dermatovenerological clinic, University Clinical center, Niš from 1st October 2019. -1st March 2020. The study comprised 29 patients with psoriasis vulgaris (11 females, 18 males). The severity of the disease was evaluated with the Psoriasis Area and Severity Index (PASI) as mean ± SD before treatment with secukinumab and ustekinumab and after 10 weeks. Dermatology Life Quality Index (DLQI) were determined at the beginning of biological treatment and after 10 weeks.
Results: The average age of participants was 49.69±12.75 years and sample consisted mainly of men (62.1%). The average disease duration among men was 16.44±10.05 years, and among women- 17.82±12.79 years. The mean DLQI decreased from 15.62 ± 7.79 to 6.34 ± 7.19 after biological treatment. The initial mean PASI and DLQI scores differed significantly from the average control scores (t-test for paired samples, p <0.0001).
Conclusion: Biological therapies of psoriasis, in addition to improving the clinical picture, demonstrated the improvement in the patients HRQoL very quickly, that should be considered during evaluating the benefits and risks of this type of therapy.
References
1. Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM; Global Psoriasis Atlas. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590. https://doi.org/10.1136/bmj.m1590
2. Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10281):1301-1315. https://doi.org/10.1016/S0140-6736(20)32549-6
3. Rendon A, Schäkel K. Psoriasis Pathogenesis and Treatment. Int J Mol Sci. 2019; 20(6):1475. https://doi.org/10.3390/ijms20061475
4. Armstrong AW, Read C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA. 2020; 323(19):1945-1960. https://doi.org/10.1001/jama.2020.4006
5. Rønholt K, Iversen L. Old and New Biological Therapies for Psoriasis. Int J Mol Sci. 2017;18(11):2297. https://doi.org/10.3390/ijms18112297
6. Spasić A, Veličković-Radovanović R, Catić-Đorđević A, Stefanović N, Cvetković T. Quality of life in type 2 diabetic patients. Acta Fac Med Naiss 2014; 31(3): 193-200. https://doi.org/10.2478/afmnai-2014-0024
7. Mei YX, Wu H, Zhang HY, Hou J, Zhang ZX, Liao W. et al. Health-related quality of life and its related factors in coronary heart disease patients: results from the Henan Rural Cohort study. Sci Rep 2021; 11(1): 5011. https://doi.org/10.1038/s41598-021-84554-6
8. Kouwenhoven TA, van der Ploeg JAM, van de Kerkhof PCM. Treatment goals in psoriasis from a patient perspective: a qualitative study. J Dermatolog Treat. 2020;31(1):13-17. https://doi.org/10.1080/09546634.2018.1544408
9. Mahmutovic J, Zukic M, Pasalic A, Brankovic S, Jaganjac A, Katana B. Correlation Between Quality of Life and Depression Among Persons Suffering from Psoriasis. Med Arch. 2017;71(5):341-346. https://doi.org/10.5455/medarh.2017.71.341-346
10. Ražnatović M, Bojanić J, Janković S. Kvalitet života obolelih od psorijaze. Biomedicinska istraživanja 2012;3(1):60-67. http://dx.doi.org//10.7251/bii1201060r
11. Zweegers J, Otero ME, van den Reek JM, Driessen RJ, Kievit W, Seyger MM. et al. Effectiveness of biologic and conventional systemic therapies in adults with chronic plaque psoriasis in daily practice: a systematic review. Acta Derm Venereol 2016; 96:453–8. https://doi.org/10.2340/00015555-2276
12. van Lümig PP, van de Kerkhof PC, Boezeman JB, Driessen RJ, de Jong EM. Adalimumab therapy for psoriasis in real‐world practice: efficacy, safety and results in biologic‐naïve vs. non‐naïve patients. J Eur Acad Dermatol Venereol 2013; 27:593–600. https://doi.org/10.1111/j.1468-3083.2012.04496.x
13. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19:210–16. https://doi.org/10.1111/j.1365-2230.1994.tb01167.x
14. Badia X, Mascaro JM, Lozano R. Measuring health‐related quality of life in patients with mild to moderate eczema and psoriasis: clinical validity, reliability and sensitivity to change of the DLQI. Br J Dermatol 1999; 141: 698–702. https://doi.org/10.1046/j.1365-2133.1999.03112.x
15. Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. Translating the science of quality of life into practice: What do dermatology life quality index scores mean? J Invest Dermatol. 2005;125(4):659-64. https://doi.org/10.1111/j.0022-202X.2005.23621.x
16. Basra MK, Salek MS, Camilleri L, Sturkey R, Finlay AY. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology. 2015; 230(1):27-33. https://doi.org/10.1159/000365390
17. Frieder J, Kivelevitch D, Fiore CT, Saad S, Menter A. The impact of biologic agents on health-related quality of life outcomes in patients with psoriasis.Expert Rev Clin Immunol. 2018;14(1):1-19. https://doi.org/10.1080/1744666X.2018.1401468
18. Norris D, Photiou L, Tacey M, Dolianitis C, Varigos G, Foley P, Baker C. Biologics and dermatology life quality index (DLQI) in the Australasian psoriasis population. J Dermatolog Treat. 2017;28(8):731-736. https://doi.org/10.1080/09546634.2017.1329501
19. Foley P, Spelman L, Murrell DF, Mate E, Tronnberg R, Lowe PM. Secukinumab treatment showed improved quality of life in patients with chronic plaque psoriasis in Australia: Results from the HOPE study. Australas J Dermatol. 2022 ;63(3):312-320. https://doi.org/10.1111/ajd.13893
20. Iskandar IYK, Ashcroft DM, Warren RB, Lunt M, McElhone K, Smith CH. et al. Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis. Br J Dermatol. 2017;177(5):1410-1421. https://doi.org/10.1111/bjd.15531
21. Jungo P, Maul JT, Djamei V, von Felten S, Kolios AGA, Czernielewsk J. et al. Superiority in Quality of Life Improvement of Biologics over Conventional Systemic Drugs in a Swiss Real-Life Psoriasis Registry. Dermatology. 2016;232(6):655-663. https://doi.org/10.1159/000455042
22. Hjalte F, Carlsson KS, Schmitt-Egenolf M. Sustained Psoriasis Area and Severity Index, Dermatology Life Quality Index and EuroQol-5D response of biological treatment in psoriasis: 10 years of real-world data in the Swedish National Psoriasis Register. Br J Dermatol. 2018;178(1):245-252. https://doi.org/10.1111/bjd.15757